Renovorx Inc (RNXT) Stock Price, Quote & News

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 284 4433

Fax: 650 397 4433

Website: renovorx.com

Address:

2570 West El Camino Real, Suite 320, Mountain View, United States

CunningStunt69 Nov. 14 at 9:56 PM

$RNXT one positive thing I will say, their inventory equates to $1.25-1.5 million in sales. Hopefully they aren’t building inventory they can’t sell. They need a lot of sales fast to keep from having to dilute again.

0 · Reply

Wolfietrader Nov. 14 at 9:12 PM

$RNXT good news is always met by a falling stock price. I’ve seen this since the IPO. The news wasn’t bad, but when they mention 2027 that spooked a lot of people.

0 · Reply

Tookoo Nov. 14 at 4:59 PM

$RNXT just a reminder, they made current revenue numbers based to 5 centers. They just locked in 14. Next quarters revenues will go up accordingly. And I don't see any real evidence or need for a reverse split, they have other options they can pursue. Also, keep in mind there are TRADERS vs INVESTORS. Traders will move in and out to make short term profits, so it'll go up and down. Investors hold the supports. *Bought 10,000 more shares this morning

3 · Reply

Rnxtsavior Nov. 14 at 3:09 PM

$RNXT reverse split announcement approaching... he will blame the not over a dollar rule. Lol.. im the bad guy

1 · Reply

CunningStunt69 Nov. 14 at 3:06 PM

$RNXT I’m losing money right now but its a little but if an F it, I’m glad its dropping. Management needs to do something other than what they are doing and the market is punishing them as it should. If it is what you say then it’s time to go find a partner or outright sell. This do almost nothing and then raise money BS ain’t gonna fly any more.

0 · Reply

BagaiCocksucker Nov. 14 at 2:42 PM

$RNXT I hope their CEO has to use his own bullshit treatment on his own ass. Maybe then they will be forced to move this shit along instead of sitting their with thumbs up their asses year after year. More testing, more testing...and more testing...

1 · Reply

Wolfietrader Nov. 14 at 2:41 PM

$RNXT brutal. Waiting another year is pushing holders out the door

0 · Reply

Rnxtsavior Nov. 14 at 1:12 PM

$RNXT wow... sheeny man just dumped 72331 shares in one trade... is that good? Asking for a friend

0 · Reply

CunningStunt69 Nov. 13 at 10:53 PM

$RNXT I genuinely believe renovocath is a billion + dollar product. What an effin tragedy if it doesn’t get there because it can’t get going fast enough.

1 · Reply

Rnxtsavior Nov. 13 at 10:29 PM

$RNXT 37150 share block... dumped.. lol

0 · Reply

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 6, 2025, 8:30 AM EST - 8 days ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 4, 2025, 8:30 AM EST - 10 days ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Oct 27, 2025, 8:30 AM EDT - 18 days ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 9, 2025, 8:30 AM EDT - 5 weeks ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Sep 25, 2025, 8:30 AM EDT - 7 weeks ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 11, 2025, 8:30 AM EDT - 2 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Aug 20, 2025, 8:30 AM EDT - 3 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 14, 2025, 4:05 PM EDT - 3 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 6, 2025, 8:30 AM EDT - 3 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Jul 28, 2025, 8:30 AM EDT - 3 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 14, 2025, 8:30 AM EDT - 4 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

May 15, 2025, 9:07 PM EDT - 6 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 6 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 8:30 AM EDT - 6 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 6, 2025, 8:30 AM EDT - 6 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 1, 2025, 8:30 AM EDT - 7 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Apr 29, 2025, 8:30 AM EDT - 7 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 16, 2025, 8:30 AM EDT - 7 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 4, 2025, 8:30 AM EDT - 8 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 1, 2025, 8:30 AM EDT - 8 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Mar 28, 2025, 8:00 AM EDT - 8 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 26, 2025, 8:00 AM EDT - 8 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 20, 2025, 8:00 AM EDT - 8 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 19, 2025, 8:00 AM EDT - 8 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Feb 26, 2025, 8:00 AM EST - 9 months ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 13, 2025, 8:00 AM EST - 9 months ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 11, 2025, 7:00 AM EST - 9 months ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 10 months ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 4:05 PM EST - 10 months ago

RenovoRx Announces Proposed Public Offering

Feb 5, 2025, 2:14 AM EST - 10 months ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Jan 27, 2025, 8:00 AM EST - 10 months ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 8, 2025, 8:00 AM EST - 11 months ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Dec 30, 2024, 8:00 AM EST - 11 months ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 14, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Jul 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Jun 26, 2024, 8:30 AM EDT - 1 year ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Jun 10, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

May 30, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Issues Update Letter to Shareholders

May 21, 2024, 9:00 AM EDT - 1 year ago

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 14, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

May 2, 2024, 9:00 AM EDT - 1 year ago

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

Apr 18, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

Apr 16, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Apr 15, 2024, 8:00 AM EDT - 1 year ago

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

CunningStunt69 Nov. 14 at 9:56 PM

0 · Reply

Wolfietrader Nov. 14 at 9:12 PM

$RNXT good news is always met by a falling stock price. I’ve seen this since the IPO. The news wasn’t bad, but when they mention 2027 that spooked a lot of people.

0 · Reply

Tookoo Nov. 14 at 4:59 PM

3 · Reply

Rnxtsavior Nov. 14 at 3:09 PM

$RNXT reverse split announcement approaching... he will blame the not over a dollar rule. Lol.. im the bad guy

1 · Reply

CunningStunt69 Nov. 14 at 3:06 PM

0 · Reply

BagaiCocksucker Nov. 14 at 2:42 PM

1 · Reply

Wolfietrader Nov. 14 at 2:41 PM

$RNXT brutal. Waiting another year is pushing holders out the door

0 · Reply

Rnxtsavior Nov. 14 at 1:12 PM

$RNXT wow... sheeny man just dumped 72331 shares in one trade... is that good? Asking for a friend

0 · Reply

CunningStunt69 Nov. 13 at 10:53 PM

$RNXT I genuinely believe renovocath is a billion + dollar product. What an effin tragedy if it doesn’t get there because it can’t get going fast enough.

1 · Reply

Rnxtsavior Nov. 13 at 10:29 PM

$RNXT 37150 share block... dumped.. lol

0 · Reply

Rnxtsavior Nov. 13 at 10:26 PM

$RNXT .89 HAHAHAHAHA

0 · Reply

brandonscience Nov. 13 at 9:51 PM

$RNXT ridiculously large ask wall at 0.93 that will never get eaten through. Tape is empty.

2 · Reply

BagaiCocksucker Nov. 13 at 9:48 PM

$RNXT Bagai needs to stick his own treatment plan up his ass at this point!

0 · Reply

Rnxtsavior Nov. 13 at 9:44 PM

$RNXT .92 cmon Brandon tell everyone why this is good. Read the script. All sells

0 · Reply

d_risk Nov. 13 at 9:34 PM

$RNXT - RenovoRx, Inc. - 10Q - Updated Risk Factors RNXT warns of potential revenue shortfalls from RenovoCath sales, highlights urgent need for substantial capital for IAG and marketing, and discloses that current cash may not fund operations beyond 12 months, raising going concern risk. #Pharmaceuticals #MarketingChallenges #GoingConcern #CapitalFunding #RevenueRisk 🟢 Added 🟠 Removed https://d-risk.ai/RNXT/10-Q/2025-11-13

0 · Reply

Wolfietrader Nov. 13 at 9:30 PM

$RNXT final data read out 2027. I want to retire next year.

1 · Reply

brandonscience Nov. 13 at 9:24 PM

$RNXT @Rnxtsavior Dude. Stop saying shitty things. I'm a high school science teacher with experience in industry and trade on the side for fun. Can we please set up a video call so you can see? I'd really like to know who you are. Let me know when you are free and I will setup a webex room for us.

2 · Reply

Wolfietrader Nov. 13 at 9:24 PM

$RNXT pot isn’t boiling yet.

0 · Reply

brandonscience Nov. 13 at 9:20 PM

$RNXT Near-term catalysts now shift to enrollment completion, registry data, investigator-initiated studies, commercialization traction, and revenue growth; the coil could be accumulation on de-risked company with no dilution, no delay, and steady commercial progress.

0 · Reply

Rnxtsavior Nov. 13 at 9:15 PM

$RNXT WOW ... OUTSTANDING... LOL.. THEY PAID THEMSELVES WELL.. THAT IS ALL I SEE.. THIS POS IS HEADING TOWARDS .50'S.... THEN WILL REVERSE SPLIT TO THE 10.00'S AND START THE STOCK SELLING SCAM ALL OVER... WITH BRANDON CHEERLEADING THE WHOLE WAY.. I'M SURE HE GETS FREE SHARES

1 · Reply

CunningStunt69 Nov. 13 at 9:11 PM

$RNXT ehhhhhh just ok, mildly disappointed.

0 · Reply

brandonscience Nov. 13 at 9:09 PM

$RNXT Press Release just out! TL;DR: neutral-to-positive: no dilution, no delays, and steady early commercialization progress. They confirmed $10M cash and runway through early 2026, TIGeR-PaC Phase 3 is still on track, and device adoption is gradually growing. It’s not a catalyst PR, so the stock probably wont spike unless they share something new in the call, but it removes downside risk and supports continued accumulation.

0 · Reply

Market Cap	35.71M
Revenue (ttm)	40,000.00
Net Income (ttm)	-8.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-22,025.00%
Debt to Equity Ratio	0.00

Volume	1,413,800
Avg Vol	619,214
Day's Range	N/A - N/A
Shares Out	36.65M
Stochastic %K	12%
Beta	1.29
Analysts	Strong Sell
Price Target	$5.62